Nefazodone Hydrochloride
FDA-approved product (tablet, oral), marketed as Nefazodone Hydrochloride, Serzone.
- Registered studies
- 6
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Major depressive disorder
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antidepressants
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae31.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
6registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Nefazodone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
NCT02977299 · start 2017-07-13
Registered record
- Registry ID
- NCT02977299
- Conditions
- Treatment Resistant Major Depressive Disorder
- Interventions
- Aripiprazole; Repetitive transcranial magnetic stimulation (rTMS); Venlafaxine XR
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2017-07-13
- Completion
- 2022-04-24
- Enrolment
- 278
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTreatment Resistant Major Depressive DisorderInterventionAripiprazole; Repetitive transcranial magnetic stimulation (rTMS); Venlafaxine XRPhasePhase 4Registry statusCompletedEffectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals
NCT00249509 · start 2000-09
Registered record
- Registry ID
- NCT00249509
- Conditions
- Marijuana Abuse
- Interventions
- Nefazodone; Bupropion
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2000-09
- Completion
- 2004-09
- Enrolment
- 132
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMarijuana AbuseInterventionNefazodone; BupropionPhasePhase 2Registry statusCompletedEffect of Nefazodone on Relapse in Females With Cocaine Abuse - 10
NCT00000293 · start 1999-01
Registered record
- Registry ID
- NCT00000293
- Conditions
- Cocaine-Related Disorders
- Interventions
- Nefazodone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1999-01
- Completion
- 2001-12
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCocaine-Related DisordersInterventionNefazodonePhasePhase 3Registry statusCompletedNefazodone in the Treatment of Cocaine Dependence and Depression - 4
NCT00015210 · start 1997-02
Registered record
- Registry ID
- NCT00015210
- Conditions
- Cocaine-Related Disorders; Substance-Related Disorders
- Interventions
- Nefazodone; Psychosocial Treatment
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1997-02
- Completion
- Not recorded
- Enrolment
- 69
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCocaine-Related Disorders; Substance-Related DisordersInterventionNefazodone; Psychosocial TreatmentPhasePhase 2Registry statusCompletedEffects of Nefazodone on Treatment of Female Cocaine Abusers - 3
NCT00000286 · start 1996-12
Registered record
- Registry ID
- NCT00000286
- Conditions
- Cocaine-Related Disorders
- Interventions
- Nefazodone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1996-12
- Completion
- 2001-12
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCocaine-Related DisordersInterventionNefazodonePhasePhase 2Registry statusCompletedNefazodone in the Treatment of Social Phobia
NCT00231348
Registered record
- Registry ID
- NCT00231348
- Conditions
- Social Anxiety Disorder (SAD)
- Interventions
- Nefazodone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- Not recorded
- Completion
- 2000-04
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSocial Anxiety Disorder (SAD)InterventionNefazodonePhasePhase 4Registry statusCompleted